There are more than 30 clinical trials ongoing of gene therapies for RDEB, but only one (B-VEC), a phase III clinical trial conducted by Krystal Biotech, directly delivers the functional version of COL7A1 gene into the skin cells to restore it. This evidence concerns the gene COL7A1 and recessive dystrophic epidermolysis bullosa.